Cullinan Therapeutics, Inc.
CGEM
$20.34
$0.703.56%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.21% | -14.50% | -15.40% | 2.08% | 7.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.47% | -2.36% | 0.38% | 13.80% | 51.51% |
| Operating Income | 24.47% | 2.36% | -0.38% | -13.80% | -51.51% |
| Income Before Tax | 23.34% | -2.39% | -6.70% | -24.78% | -66.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.34% | -2.39% | -6.43% | -24.78% | -66.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.34% | -2.39% | -6.43% | -24.78% | -66.69% |
| EBIT | 24.47% | 2.36% | -0.38% | -13.80% | -51.51% |
| EBITDA | 24.49% | 2.37% | -0.38% | -13.81% | -51.59% |
| EPS Basic | 24.26% | -1.36% | -5.31% | -23.21% | -40.12% |
| Normalized Basic EPS | 26.43% | 0.25% | -5.58% | -23.22% | -55.50% |
| EPS Diluted | 24.26% | -1.36% | -5.31% | -23.21% | -40.12% |
| Normalized Diluted EPS | 26.43% | 0.25% | -5.58% | -23.22% | -55.50% |
| Average Basic Shares Outstanding | 4.20% | 2.65% | 1.06% | 1.27% | 7.20% |
| Average Diluted Shares Outstanding | 4.20% | 2.65% | 1.06% | 1.27% | 7.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |